### Section: Prescription Drugs  
### Subsection: Endocrine and Metabolic Drugs  
### Subject: Ravicti

**Effective Date:** April 1, 2019  
**Original Policy Date:** November 8, 2013  
**Page:** 1 of 3

**Last Review Date:** March 15, 2019

---

# Ravicti

## Description

**Ravicti (glycerol phenylbutyrate)**

## Background

Urea cycle disorders (UCDs) are genetic disorders that involve deficiencies of specific enzymes involved in the urea cycle, a series of biochemical steps normally required to remove ammonia from the blood. When protein is absorbed and broken down by the body, it produces nitrogen as a waste product. The urea cycle removes nitrogen from the blood and converts it to urea, which is removed from the body through urine. In people with UCDs, nitrogen accumulates and remains in the body as ammonia, which can travel to the brain and cause brain damage, or coma (1).

Ravicti, a liquid taken three times a day with meals, helps dispose of ammonia in the body. It is intended for patients whose UCD cannot be managed by a protein-restricted diet or amino acid supplements alone. Ravicti must be used with a protein-restricted diet and, in some cases, dietary supplements (1).

## Regulatory Status

**FDA approved indication:** Ravicti is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements) (1).

## Limitations of Use:
Ravicti is not indicated for treatment of acute hyperammonemia in patients with UCDs. Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established (1).

**Related policies**

**Policy**

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Ravicti may be considered **medically necessary** in patients with the diagnosis of urea cycle disorders (UCDs) and if the conditions indicated below are met.

Ravicti is considered **investigational** for all other indications.

**Prior-Approval Requirements**

**Diagnosis**

Patient must have the following:

- Urea cycle disorders (UCDs)

**AND ALL** of the following:

1. Failure to control ammonia level with dietary restrictions and/or amino acid supplementation
2. Prescribing physician should be experienced in the management of UCDs
3. Must be used with dietary protein restrictions

**Policy Guidelines**

**Pre - PA Allowance**

None

**Prior - Approval Limits**

Duration Lifetime

**Rationale**
Summary
Ravicti is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). Ravicti is not indicated for treatment of acute hyperammonemia in patients with UCDs. Safety and efficacy for treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Ravicti while maintaining optimal therapeutic outcomes.

References

Policy History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2013</td>
<td>Addition to PA</td>
</tr>
<tr>
<td>December 2013</td>
<td>Annual editorial review.</td>
</tr>
<tr>
<td>December 2014</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>June 2015</td>
<td>Annual editorial review and reference update</td>
</tr>
<tr>
<td>September 2016</td>
<td>Annual editorial review and reference update; Policy code changed from 5.08.29 to 5.30.29</td>
</tr>
<tr>
<td>June 2017</td>
<td>Change of the age requirement from 2 years to 2 months</td>
</tr>
<tr>
<td>September 2017</td>
<td>Annual review</td>
</tr>
<tr>
<td>November 2018</td>
<td>Annual review and reference update</td>
</tr>
<tr>
<td>January 2019</td>
<td>Removal of age requirement</td>
</tr>
<tr>
<td>March 2019</td>
<td>Annual review</td>
</tr>
</tbody>
</table>

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 15, 2019 and is effective on April 1, 2019.